These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37866812)

  • 1. Circulating tumor DNA, and clinical features to guide rechallenge with BRAF inhibitors in BRAF-V600E mutated metastatic colorectal cancer.
    Ros J; Vivancos A; Tabernero J; Élez E
    Ann Oncol; 2024 Feb; 35(2):240-241. PubMed ID: 37866812
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of BRAF
    Liposits G; Winther SB; Ryg J; Skuladottir H; Möller S; Hofsli E; Shah CH; Poulsen LØ; Berglund Å; Qvortrup C; Osterlund P; Glimelius B; Sorbye H; Pfeiffer P
    J Geriatr Oncol; 2024 Mar; 15(2):101632. PubMed ID: 37730481
    [No Abstract]   [Full Text] [Related]  

  • 3. Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with Irinotecan Dose Escalation versus FOLFOXIRI Plus Bevacizumab in
    Tsai HL; Huang CW; Chen YC; Su WC; Chang TK; Chen PJ; Li CC; Chang YT; Wang JY
    Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138211
    [No Abstract]   [Full Text] [Related]  

  • 4. BRAF-mutated metastatic colorectal cancer between past and future.
    Cremolini C; Di Maio M; Petrelli F; Berenato R; Loupakis F; Pietrantonio F
    Br J Cancer; 2015 Dec; 113(11):1634-5. PubMed ID: 26355234
    [No Abstract]   [Full Text] [Related]  

  • 5. Device-assisted Full Thickness R0 Resection of BRAF (V600E)-Mutated T3 Colorectal Cancer in the Ascending Colon.
    Zimmer V; Schuld J
    J Gastrointestin Liver Dis; 2023 Dec; 32(4):431. PubMed ID: 38147597
    [No Abstract]   [Full Text] [Related]  

  • 6. Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer.
    Patelli G; Mauri G; Tosi F; Amatu A; Bencardino K; Bonazzina E; Pizzutilo EG; Villa F; Calvanese G; Agostara AG; Stabile S; Ghezzi S; Crisafulli G; Di Nicolantonio F; Marsoni S; Bardelli A; Siena S; Sartore-Bianchi A
    Clin Cancer Res; 2023 Nov; 29(22):4530-4539. PubMed ID: 37436743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and pathologic features correlated with rare favorable survival in patients with
    Morris V; Kee B; Overman M; Dasari A; Raghav K; Johnson B; Parseghian C; Wolff RA; Garg N; Eng C; Kopetz S
    J Gastrointest Oncol; 2022 Apr; 13(2):647-656. PubMed ID: 35557581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific activation of glycolytic enzyme enolase 2 in BRAF V600E-mutated colorectal cancer.
    Yukimoto R; Nishida N; Hata T; Fujino S; Ogino T; Miyoshi N; Takahashi H; Uemura M; Satoh T; Hirofumi Y; Mizushima T; Doki Y; Eguchi H
    Cancer Sci; 2021 Jul; 112(7):2884-2894. PubMed ID: 33934428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study.
    Eriksen M; Pfeiffer P; Rohrberg KS; Yde CW; Petersen LN; Poulsen LØ; Qvortrup C
    BMC Cancer; 2022 Dec; 22(1):1321. PubMed ID: 36527039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the therapy of BRAF
    Jin Z; Sinicrope FA
    Expert Rev Anticancer Ther; 2019 Sep; 19(9):823-829. PubMed ID: 31455117
    [No Abstract]   [Full Text] [Related]  

  • 11. REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer.
    Nakajima H; Kotani D; Bando H; Kato T; Oki E; Shinozaki E; Sunakawa Y; Yamazaki K; Yuki S; Nakamura Y; Yamanaka T; Yoshino T; Ohta T; Taniguchi H; Kagawa Y
    BMC Cancer; 2021 Jun; 21(1):674. PubMed ID: 34098908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF V600E-mutated Colorectal Neuroendocrine Carcinoma Effectively Treated with a Chemotherapy Protocol for BRAF-mutated Metastatic Colorectal Cancer.
    Owaki S; Mori Y; Nakai S; Maeda H; Imazu M; Tomita Y; Kanaiwa H; Yamaguchi A; Kitagawa M; Hirano A; Kimura Y; Tsuchida K; Kataoka H
    Intern Med; 2024 Jul; 63(14):1995-1999. PubMed ID: 37981300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF
    Gourdin G; Chotel L; de la Fouchardière C
    Adv Ther; 2023 Aug; 40(8):3281-3290. PubMed ID: 37316651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.
    Cremolini C; Di Bartolomeo M; Amatu A; Antoniotti C; Moretto R; Berenato R; Perrone F; Tamborini E; Aprile G; Lonardi S; Sartore-Bianchi A; Fontanini G; Milione M; Lauricella C; Siena S; Falcone A; de Braud F; Loupakis F; Pietrantonio F
    Ann Oncol; 2015 Oct; 26(10):2092-7. PubMed ID: 26153495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic Features and Prognosis of
    Guan WL; Qiu MZ; He CY; Yang LQ; Jin Y; Wang ZQ; Li YH; Xu RH; Wang FH
    Front Oncol; 2020; 10():563407. PubMed ID: 33330032
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
    Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
    Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Recent Advances and Future Strategies.
    Morris VK
    Curr Colorectal Cancer Rep; 2019 Apr; 15(2):53-60. PubMed ID: 31762713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-sensitivity PCR method for detecting BRAF V600E mutations in metastatic colorectal cancer using LNA/DNA chimeras to block wild-type alleles.
    Chen D; Huang JF; Xia H; Duan GJ; Chuai ZR; Yang Z; Fu WL; Huang Q
    Anal Bioanal Chem; 2014 Apr; 406(9-10):2477-87. PubMed ID: 24500755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.
    Tang Z; Yuan X; Du R; Cheung SH; Zhang G; Wei J; Zhao Y; Feng Y; Peng H; Zhang Y; Du Y; Hu X; Gong W; Liu Y; Gao Y; Liu Y; Hao R; Li S; Wang S; Ji J; Zhang L; Li S; Sutton D; Wei M; Zhou C; Wang L; Luo L
    Mol Cancer Ther; 2015 Oct; 14(10):2187-97. PubMed ID: 26208524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. European expert panel consensus on the clinical management of BRAF
    Martinelli E; Arnold D; Cervantes A; Stintzing S; Van Cutsem E; Tabernero J; Taieb J; Wasan H; Ciardiello F
    Cancer Treat Rev; 2023 Apr; 115():102541. PubMed ID: 36931147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.